| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9101591 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9339551 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9168305 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9220784 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9132110 | HORIZON | Treatment of pain with topical diclofenac |
Oct, 2027
(3 years from now) | |
| US9066913 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9339552 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9168304 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US9539335 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US8871809 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US8563613 | HORIZON | Diclofenac topical formulation |
Oct, 2027
(3 years from now) | |
| US8252838 | HORIZON | Diclofenac topical formulation |
Apr, 2028
(4 years from now) | |
| US8741956 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
| US8217078 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
| US9370501 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
| US9415029 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
| US9375412 | HORIZON | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
| US8618164 | HORIZON | Treatment of pain with topical diclofenac compounds |
Jul, 2029
(5 years from now) | |
| US8546450 | HORIZON | Treatment of pain with topical diclofenac compounds |
Aug, 2030
(6 years from now) | |
Pennsaid is owned by Horizon.
Pennsaid contains Diclofenac Sodium.
Pennsaid has a total of 19 drug patents out of which 0 drug patents have expired.
Pennsaid was authorised for market use on 16 January, 2014.
Pennsaid is available in solution;topical dosage forms.
Pennsaid can be used as use of topical diclofenac sodium for treating pain, use of topical diclofenac on the knee and a second topical prescription medication on the same knee, use of topical diclofenac for treating pain, combination use of topical diclofenac on the knee and administration of an oral nsaid., use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant, use of topical diclofenac on a joint for treating osteoarthritis.
The generics of Pennsaid are possible to be released after 09 August, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 16, 2017 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 16 January, 2014
Treatment: Use of topical diclofenac for treating pain; Use of topical diclofenac sodium for treating pain; Use of topical diclofenac on a joint for treating osteoarthritis; Combination use of topical diclofenac...
Dosage: SOLUTION;TOPICAL
PENNSAID family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618164 | NUVO PHARMS INC | Treatment of pain with topical diclofenac compounds |
Jul, 2029
(5 years from now) | |
| US8217078 | NUVO PHARMS INC | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
| US8741956 | NUVO PHARMS INC | Treatment of pain with topical diclofenac |
Jul, 2029
(5 years from now) | |
| US8546450 | NUVO PHARMS INC | Treatment of pain with topical diclofenac compounds |
Aug, 2030
(6 years from now) | |
Pennsaid is owned by Nuvo Pharms Inc.
Pennsaid contains Diclofenac Sodium.
Pennsaid has a total of 4 drug patents out of which 0 drug patents have expired.
Pennsaid was authorised for market use on 04 November, 2009.
Pennsaid is available in solution;topical dosage forms.
Pennsaid can be used as use of topical diclofenac on the knee and a second topical medication on the same knee, use of topical diclofenac on the knee and a second topical prescription medication on the same knee, combination use of topical diclofenac on the knee and administration of an oral nsaid., use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant.
The generics of Pennsaid are possible to be released after 09 August, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Nov 04, 2012 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 04 November, 2009
Treatment: Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Use of topical diclofenac on the knee and a second topical medication on the same knee; Combination...
Dosage: SOLUTION;TOPICAL
PENNSAID family patents